Plasma repressor element 1-silencing transcription factor levels are decreased in patients with Alzheimer's disease.
Alzheimer's disease
Cognition
Medial temporal lobe atrophy
Repressor element 1-silencing transcription
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
received:
07
02
2021
accepted:
24
05
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Repressor element 1-silencing transcription (REST)/neuron-restrictive silencer factor is considered a new therapeutic target for neurodegenerative disorders such as Alzheimer's disease (AD). However, the relationship between AD and REST remains unclear. This study aimed to 1) examine plasma REST levels and REST gene levels in AD patients and 2) further explore the pathological relationships between REST protein levels and cognitive decline in clinical conditions, including medial temporal lobe atrophy. Participants (n = 252, mean age 68.95 ± 8.78 years) were recruited in Beijing, China, and then divided into a normal cognition (NC) group (n = 89), an amnestic mild cognitive impairment (aMCI) group (n = 79), and an AD dementia group (n = 84) according to diagnostic criteria. All participants underwent neuropsychological assessments, laboratory tests, and neuroimaging scans (magnetic resonance imaging) at baseline. Plasma REST protein levels and the distribution of REST single nucleotide polymorphisms (SNPs) were compared among the three groups. Correlations between cognitive function, neuro-imaging results, and REST levels were determined by a multivariate linear regression analysis. The plasma REST levels in both the NC group (430.30 ± 303.43)pg/ml and aMCI group (414.27 ± 263.39)pg/ml were significantly higher than that in the AD dementia group (NC vs AD dementia group, p = 0.034; aMCI vs AD dementia group, p = 0.033). There was no significant difference between the NC and aMCI groups (p = 0.948). No significant difference was found among the three groups regarding the genotype distribution (rs2227902 and rs3976529 SNPs) of the REST gene. The REST level was correlated with the left medial temporal lobe atrophy index (r = 0.306, p = 0.023). After 6 months of follow-up, the REST level in the NC group was positively correlated with the change in the Mini-Mental State Examination score (r = 0.289, p = 0.02). The plasma REST protein level is decreased in AD dementia patients, which is associated with memory impairment and left temporal lobe atrophy and may have potential value for clinical diagnosis of AD dementia.
Sections du résumé
BACKGROUND
Repressor element 1-silencing transcription (REST)/neuron-restrictive silencer factor is considered a new therapeutic target for neurodegenerative disorders such as Alzheimer's disease (AD). However, the relationship between AD and REST remains unclear. This study aimed to 1) examine plasma REST levels and REST gene levels in AD patients and 2) further explore the pathological relationships between REST protein levels and cognitive decline in clinical conditions, including medial temporal lobe atrophy.
METHODS
Participants (n = 252, mean age 68.95 ± 8.78 years) were recruited in Beijing, China, and then divided into a normal cognition (NC) group (n = 89), an amnestic mild cognitive impairment (aMCI) group (n = 79), and an AD dementia group (n = 84) according to diagnostic criteria. All participants underwent neuropsychological assessments, laboratory tests, and neuroimaging scans (magnetic resonance imaging) at baseline. Plasma REST protein levels and the distribution of REST single nucleotide polymorphisms (SNPs) were compared among the three groups. Correlations between cognitive function, neuro-imaging results, and REST levels were determined by a multivariate linear regression analysis.
RESULTS
The plasma REST levels in both the NC group (430.30 ± 303.43)pg/ml and aMCI group (414.27 ± 263.39)pg/ml were significantly higher than that in the AD dementia group (NC vs AD dementia group, p = 0.034; aMCI vs AD dementia group, p = 0.033). There was no significant difference between the NC and aMCI groups (p = 0.948). No significant difference was found among the three groups regarding the genotype distribution (rs2227902 and rs3976529 SNPs) of the REST gene. The REST level was correlated with the left medial temporal lobe atrophy index (r = 0.306, p = 0.023). After 6 months of follow-up, the REST level in the NC group was positively correlated with the change in the Mini-Mental State Examination score (r = 0.289, p = 0.02).
CONCLUSION
The plasma REST protein level is decreased in AD dementia patients, which is associated with memory impairment and left temporal lobe atrophy and may have potential value for clinical diagnosis of AD dementia.
Identifiants
pubmed: 35650520
doi: 10.1186/s12877-022-03163-8
pii: 10.1186/s12877-022-03163-8
pmc: PMC9158200
doi:
Substances chimiques
RE1-silencing transcription factor
0
Repressor Proteins
0
Transcription Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
471Informations de copyright
© 2022. The Author(s).
Références
J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72
pubmed: 1431963
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Ann Clin Transl Neurol. 2016 Apr 13;3(5):399-403
pubmed: 27231710
Front Aging Neurosci. 2014 Mar 24;6:23
pubmed: 24715861
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):714-8
pubmed: 16549412
Br J Psychiatry. 1982 Jun;140:566-72
pubmed: 7104545
Arch Neurol. 2008 Jul;65(7):963-7
pubmed: 18625866
Eur Radiol. 2011 Dec;21(12):2618-25
pubmed: 21805370
BMC Geriatr. 2019 Feb 28;19(1):59
pubmed: 30819102
Epilepsy Behav. 2016 Jan;54:117-27
pubmed: 26708060
Sci Rep. 2017 Aug 25;7(1):9530
pubmed: 28842657
BMC Psychiatry. 2014 Mar 10;14:71
pubmed: 24612772
J Intern Med. 2015 Sep;278(3):277-90
pubmed: 25752192
Transl Psychiatry. 2017 Jun 6;7(6):e1148
pubmed: 28585932
Ann Neurol. 2015 Oct;78(4):661-2
pubmed: 26179831
Int J Geriatr Psychiatry. 2015 Aug;30(8):888-90
pubmed: 26172064
J Am Geriatr Soc. 2018 Jan;66(1):92-99
pubmed: 29135021
Ann Clin Transl Neurol. 2015 Jul;2(7):769-73
pubmed: 26273689
JAMA Intern Med. 2015 Sep;175(9):1450-8
pubmed: 26052687
Ann Neurol. 2015 Mar;77(3):547-52
pubmed: 25559091
Nature. 2014 Mar 27;507(7493):448-54
pubmed: 24670762
Alzheimers Dement (Amst). 2016 May 07;3:63-72
pubmed: 27408937
J Clin Exp Neuropsychol. 2002 Apr;24(2):214-20
pubmed: 11992204
J Am Geriatr Soc. 1989 Aug;37(8):730-4
pubmed: 2754158
Mov Disord. 2014 Jun;29(7):869
pubmed: 24833024